Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022
Insulin Lispro Injection can be ordered through all U.S. retail pharmacies
Monthly prescriptions for all Lilly insulins — including Insulin Lispro Injection — remain available for $35 through the Lilly Insulin Value Program and the Medicare Part D Senior Savings Model

Eli Lilly and Company (NYSE: LLY) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022, effectively bringing the list price down to 2008 levels. The new list price will apply to all Lilly’s non-branded insulins, including Insulin Lispro Injection, a lower list-priced alternative to Humalog U-100.

The new lower list price is the latest among numerous options that can reduce out-of-pocket costs for Lilly insulin at U.S. retail pharmacies. People using any Lilly insulin – including Insulin Lispro Injection – can fill their monthly prescription for $35 through the Lilly Insulin Value Program for people with commercial insurance or who are uninsured, and the Senior Savings Model for seniors in participating Medicare Part D plans.

The new list price for Insulin Lispro Injection will be $82.41 for individual vials and $159.12 for a pack of five pens – which is 70 percent less than Lilly’s branded Humalog U-100 counterparts and can help people who have not activated one of Lilly’s affordability solutions.

“Lilly has introduced numerous affordability programs since 2017. Collectively, these solutions are significantly lowering the out-of-pocket costs for people using our insulins,” said David A. Ricks, Lilly’s chairman and CEO. “Today’s list price cut can further help people who are exposed within our healthcare system – the underinsured and uninsured. Half list-priced Insulin Lispro Injection has been adopted by a third of Humalog U-100 consumers. We hope this additional 40 percent cut can expand affordable insulin to more people with diabetes.”

Lilly’s numerous affordability solutions, combined with insurance coverage, have lowered the average monthly out-of-pocket cost for a prescription of Lilly insulin (regardless of the number of vials or pens) to $28.05, a 27 percent decrease over the past four years. In addition to lowering the list price of Insulin Lispro Injection, Lilly will keep other affordability programs in place for people using Lilly insulins – including the $35 co-pay card for the uninsured and people with commercial insurance, and the Senior Savings Model for people in participating Medicare Part D plans.

Insulin Lispro Injection Access
All major wholesalers stock and deliver Insulin Lispro Injection to U.S. pharmacies, and payers will continue to have the opportunity to make the lower list-priced insulins available to people living with diabetes. Pharmacists can substitute Insulin Lispro Injection U-100 for Humalog U-100 without a new prescription because they are the same insulin. Any retail pharmacy that does not stock Insulin Lispro Injection can obtain it from a wholesaler in 1-2 days.

Approximately 1 in 3 prescriptions for Lilly’s U-100 mealtime insulin – Lilly’s most commonly used insulin formulation – is for Insulin Lispro Injection.

The greatest benefit will be seen by people who face higher out-of-pocket costs – such as people without insurance and those with high deductible plans or co-insurance. Most people using Insulin Lispro Injection are unlikely to see a change in what they pay for their monthly prescription because they have fixed insurance co-pays or already use one of Lilly’s affordability programs. Therefore, people should continue to refill insulin prescriptions at their normal pace. Given that out-of-pocket costs at the pharmacy can vary greatly due to insurance plan designs and co-pays, people should ask their pharmacist whether these lower list-priced options reduce their out-of-pocket costs.

“The affordability options we have introduced in recent years have helped many people who were struggling to afford their insulin,” said Mike Mason, president, Lilly Diabetes. “Regardless of their circumstances, people who cannot afford their Lilly insulin should call the Lilly Diabetes Solution Center, or go to, to find solutions to help them lower their out-of-pocket costs.”

About Diabetes
Approximately 34 million Americans1 (just over 1 in 10) and an estimated 463 million adults worldwide2 have diabetes. Type 2 diabetes is that the commonest type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases within the us alone.2 Diabetes may be a chronic disease that happens when the body doesn’t properly produce or use the hormone insulin.

About Lilly Diabetes
Lilly has been a worldwide leader in diabetes care since 1923, once we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to satisfy the various needs of individuals with diabetes and people who look after them. Through research, collaboration and quality manufacturing we attempt to form life better for people suffering from diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more.
About Eli Lilly and Company
Lilly may be a global health care leader that unites caring with discovery to make medicines that make life better for people round the world. We were founded quite a century ago by a person committed to making high-quality medicines that meet real needs, and today we remain faithful that mission altogether our work. Across the world , Lilly employees work to get and convey life-changing medicines to those that need them, improve the understanding and management of disease, and provides back to communities through philanthropy and volunteerism.

Source link: